Markets:

Overview

News

Currencies

International

Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

311.27 +5.56 (+1.82%)

Streaming Delayed Price Updated: 10:03 AM EDT, May 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗

May 10, 2026

This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗

May 10, 2026

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.

Via The Motley Fool

Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum ↗

May 09, 2026

Via Chartmill

Krystal (KRYS) Q1 2026 Earnings Transcript ↗

May 04, 2026

Krystal (KRYS) Q1 2026 Earnings Transcript

Via The Motley Fool

Krystal Biotech (NASDAQ:KRYS) Surges After Q1 Beat as VYJUVEK Revenue Hits $116.4M ↗

May 04, 2026

Via Chartmill

Krystal (KRYS) Q1 2025 Earnings Transcript ↗

May 04, 2026

Krystal (KRYS) Q1 2025 Earnings Transcript

Via The Motley Fool

Is Paymentus Stock a Buy After Palisades Investment Partners Increased Its Stake By $6 Million? ↗

May 01, 2026

Paymentus delivers cloud-based bill payment technology to major enterprises across regulated and service-intensive industries.

Via The Motley Fool

Topics Regulatory Compliance

Is Amprius Technologies Stock a Buy After Palisades Investment Partners Initiated a Position Worth $4.8 Million? ↗

May 01, 2026

Amprius Technologies manufactures silicon nanowire lithium-ion batteries for aerospace, defense, and electric mobility markets.

Via The Motley Fool

Topics Electric Vehicles Regulatory Compliance

Krystal Biotech Inc (NASDAQ:KRYS) Reports Q4 2025 Earnings Beat and Key Pipeline Advancements ↗

February 17, 2026

Via Chartmill

Topics Earnings

Palisades Investment Partners Initiated a Position in SkyWater Technology Stock. What Does This Mean for Investors? ↗

May 01, 2026

SkyWater Technology delivers custom semiconductor solutions for sectors including aerospace, automotive, and industrial IoT.

Via The Motley Fool

Topics Regulatory Compliance

3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗

April 16, 2026

These companies boast significant upside potential.

Via The Motley Fool

Is Vertex Pharmaceuticals' Empire in Trouble? ↗

April 16, 2026

It might not be too late to invest in this company.

Via The Motley Fool

Could This Under-the-Radar Healthcare Stock Set You Up for Life? ↗

April 07, 2026

The biotech is off to a pretty decent start.

Via The Motley Fool

Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

March 23, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗

March 16, 2026

Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗

March 16, 2026

This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.

Via The Motley Fool

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.

Via The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗

February 22, 2026

This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.

Via The Motley Fool

Topics Regulatory Compliance

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

February 22, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗

February 22, 2026

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗

February 22, 2026

Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism ↗

February 17, 2026

Jefferies’ new price target represents a potential upside of about 34% from the stock’s closing price on Friday.

Via Stocktwits

Topics Artificial Intelligence

Krystal Biotech (KRYS) Q4 2025 Earnings Transcript ↗

February 17, 2026

Krystal Biotech (KRYS) Q4 2025 Earnings Transcript

Via The Motley Fool

Got $300? 2 Biotech Stocks to Buy and Hold Forever ↗

February 16, 2026

These two biotechs only have one marketable therapy each, but both have blockbuster potential.

Via The Motley Fool

Soleus Adds a Significant Number of Celcuity Shares ↗

February 13, 2026

This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.

Via The Motley Fool

Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗

January 25, 2026

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

Via The Motley Fool

Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗

January 24, 2026

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

Via The Motley Fool

Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Drop ↗

December 19, 2025

The timing looks painful, but the fundamentals tell a more complicated story about why long-term investors are still paying attention.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Is IPG Photonics Stock a Buy as One Fund Builds a $9 Million Stake in the Firm? ↗

December 19, 2025

A sharp rebound in margins and profitability is testing whether patience can finally pay off for investors willing to look past years of volatility.

Via The Motley Fool

Topics Regulatory Compliance

Why One Fund Has an $8.5 Million Bet on Five9 Despite a 50% One-Year Stock Collapse ↗

December 19, 2025

The stock’s collapse tells one story, but the underlying business metrics suggest a very different long-term setup.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.